Although these biomarkers, including CRP, CAR, GPS, PNI, and NLR, have shown prognostic value in various treatment settings for diverse cancers, including esophageal cancer [30–34], they have gained more attention recently with regard to immune-oncology treatment. The gene discussed is CRP; the disease is esophageal cancer.